NCT05188872 Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
| NCT ID | NCT05188872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Positron-Emission Tomography |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2020-09-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary aldosteronism is the most common cause of secondary hypertension. The two main types of primary aldosteronism are aldosteronoma(30%) and adrenal hyperplasia(60%). The gold standard that determines the diagnosis and treatment strategy of primary aldosteronism is adrenal vein sampling(AVS), but the success rate is only about 80%. Using CXCR4 as a probe for 68Ga-Pentixafor PET/CT imaging can guide the classification diagnosis and treatment strategy of primary aldosteronism, which is a favorable supplement to AVS. Superselective adrenal artery embolization(SAAE) and laparoscopy are the main operation treatments for primary aldosteronism. SAAE is an invasive interventional operation. It is a novel way to evaluate the changes in the structure and function of adrenal tissue pre-postoperative SAAE by using the changes in 68Ga-Pentixafor PET/CT imaging.
Eligibility Criteria
Inclusion Criteria: * adult population (aged 18 years or order); * patients with suspected or new diagnosed Primary aldosteronism (supporting evidence may include MRI, CT, laboratory tests); * patients who had scheduled 68Ga-BNU-PSMA PET/CT scan; * patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee; * healthy volunteers(aged 18 years or order). Exclusion Criteria: * patients with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Contact & Investigator
Liangdi Xie, MD
STUDY CHAIR
The First Affiliated Hospital, Fujian Medical University
Frequently Asked Questions
Who can join the NCT05188872 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 90 Years, studying Positron-Emission Tomography. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05188872 currently recruiting?
Yes, NCT05188872 is actively recruiting participants. Contact the research team at miaoweibing@126.com for enrollment information.
Where is the NCT05188872 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT05188872 clinical trial?
NCT05188872 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Liangdi Xie, MD at The First Affiliated Hospital, Fujian Medical University. The trial plans to enroll 100 participants.